改良电痉挛治疗精神分裂症的疗效及对患者血清细胞因子、 C-反应蛋白水平的影响
|
摘要
目的:观察改良电痉挛(MECT)对精神分裂症患者的治疗效果,及对C-反应蛋白等细胞因子水平的影响。方法:回顾性分析2016年1月-2017年9月在我院接受治疗的精神分裂症患者的临床资料,根据其治疗方式分为药物治疗组和MECT组。观察两组患者治疗前后PANSS、MCCB评分、C-反应蛋白等细胞因子水平的差异。结果:两组患者治疗前PANSS总分和各因子得分无明显差别,治疗后,MECT组患者的PANSS总分、阳性症状得分、阴性症状得分和精神病理症状得分均低于药物治疗组(t=10.002,4.902,6.584,6.778;P<0.001);两组患者治疗前C-反应蛋白等细胞因子水平无差别,治疗后,MECT组的IL-6、IL-18和CRP水平低于药物治疗组(t=8.291,14.875,9.331;P<0.001);两组患者治疗前智力得分无差别,治疗后,MECT组智力得分高于药物治疗组(t=-5.032,P<0.05)。结论:改良电痉挛对精神分裂症患者有较好的治疗效果,可明显改善患者的C-反应蛋白和智力水平,具有良好的临床应用价值。
Objective:To observe the effect of modified electrospasm(MECT)on the treatment of schizophrenic patients and to the level of cytokines such as C-reactive protein.Methods:The clinical data of schizophrenic patients who received treatment in our hospital from January 2016 to September 2017 were retrospectively analyzed.They were divided into drug treatment group and MECT group according to their treatment.The differences in the levels of PANSS,MCCB and C-reactive protein were observed in the two groups of patients before and after treatment.Results:PANSS score and each factor score had no significant difference between the two groups of patients before treatment(P>0.05);After treatment,PANSS total score,positive symptom score,negative symptom scores and psychiatric symptoms scores were lower in the patients in the MECT group than the treatment group(t=10.002,4.902,6.584,6.778,P<0.05);There was no difference in the levels of C-reactive protein and other cytokines in the two groups before treatment(P>0.05).After treatment,the levels of IL-6,IL-18 and CRP in group MECT were lower than those in the drug treatment group(t=8.291,14.875,9.331,P<0.001).There was no difference in intelligence scores between the two groups before treatment(P>0.05).After treatment,the intelligence score of group MECT was higher than that of the drug treatment group(t=-5.032,P<0.05).Conclusion:Modified electroconvulsive therapy has a good therapeutic effect on schizophrenia patients.It can significantly improve the C-reactive protein and intelligence level of patients.
Objective:To observe the effect of modified electrospasm(MECT)on the treatment of schizophrenic patients and to the level of cytokines such as C-reactive protein.Methods:The clinical data of schizophrenic patients who received treatment in our hospital from January 2016 to September 2017 were retrospectively analyzed.They were divided into drug treatment group and MECT group according to their treatment.The differences in the levels of PANSS,MCCB and C-reactive protein were observed in the two groups of patients before and after treatment.Results:PANSS score and each factor score had no significant difference between the two groups of patients before treatment(P>0.05);After treatment,PANSS total score,positive symptom score,negative symptom scores and psychiatric symptoms scores were lower in the patients in the MECT group than the treatment group(t=10.002,4.902,6.584,6.778,P<0.05);There was no difference in the levels of C-reactive protein and other cytokines in the two groups before treatment(P>0.05).After treatment,the levels of IL-6,IL-18 and CRP in group MECT were lower than those in the drug treatment group(t=8.291,14.875,9.331,P<0.001).There was no difference in intelligence scores between the two groups before treatment(P>0.05).After treatment,the intelligence score of group MECT was higher than that of the drug treatment group(t=-5.032,P<0.05).Conclusion:Modified electroconvulsive therapy has a good therapeutic effect on schizophrenia patients.It can significantly improve the C-reactive protein and intelligence level of patients.
引文
[1]Grassi G,Poli L,Cantisani A,et al.Hypochondriasis and obsessive-compulsive disorder in schizophrenic patients treated with clozapine vs other atypical antipsychotics[J].CNS Spectrums,2014,19(04):340-346
[2]Haroche A.Nitroprusside treatment of schizophrenic patients[J].Soins Psychiatrie,2013,254(287):6-11
[3]梅其一,陈魁,沈建红,等.精神分裂症患者棕榈酸帕利哌酮注射液中断治疗的相关因素分析[J].中华精神科杂志,2016,49(6):373-377
[4]谭樨.帕利哌酮联合无抽搐电痉挛治疗对精神分裂症患者记忆力的影响研究[J].四川医学,2015,36(11):1524-1526
[5]姜玮,路亚洲,史晓宁,等.精神分裂症患者临床特征和无抽搐电痉挛治疗刺激参数对疗效影响[J].中国健康心理学杂志,2014,22(10):1470-1472
[6]李东.氯氮平与MECT控制精神分裂症兴奋症状对照研究[J].中国现代药物应用,2015,9(19):132-133
[7]Dubois V,Peuskens J,Geerts P,et al.Clinical outcomes of long-acting risperidone in recent versus long-term diagnosed Belgian schizophrenic patients:Results from electronic Schizophrenia Treatment Adherence Registry(e-STAR)and trial for the initiation and maintenance of remission in schi[J].Early Intervention in Psychiatry,2014,8(1):39-49
[8]张璐璐,赵靖平.精神分裂症阴性症状的相关生物学机制与药物治疗的新发现[J].中华医学杂志,2015,95(35):2890-2892
[9]Toledo-Romero F,Molina J,López-Rodríguez E,et al.Augmentation with amisulpride for schizophrenic patients non-responsive to risperidone monotherapy[J].Pharmacopsychiatry,2015,48(2):51-57
[10]郭永芳,周小东,付华斌,等.改良电痉挛治疗对精神分裂症患者血清细胞因子及C-反应蛋白水平的影响[J].四川精神卫生,2015,28(2):119-122
[11]姜玮,路亚洲,李艳茹,等.无抽搐电痉挛治疗精神分裂症量效关系及早期预测[J].中国健康心理学杂志,2014,22(10):1473-1474
[12]肖文焕,李金,张晓斌,等.无抽搐电休克对精神分裂症患者血清脑源性神经营养因子的影响[J].国际精神病学杂志,2016,43(1):1-3
[13]董玲,安翠霞,王学义.精神分裂症认知功能损害的非药物治疗研究进展[J].中华精神科杂志,2014,47(1):56-58
[14]高海英,张淑艳,张继青,等.改良电痉挛治疗结合心理护理治疗精神分裂症的对照分析[J].河北医药,2014,36(23):3674-3675
[15]曹宏波,崔林梅,黄自州,等.齐拉西酮联合无抽搐电休克治疗精神分裂症的血清指标及电生理特征评价[J].海南医学院学报,2017,23(6):847-850
[16]强瑞香,高海江,刘炳书,等.改良电痉挛治疗与686项目结合治疗精神分裂症阳性症状[J].中国健康心理学杂志,2014,22(5):658-660
[2]Haroche A.Nitroprusside treatment of schizophrenic patients[J].Soins Psychiatrie,2013,254(287):6-11
[3]梅其一,陈魁,沈建红,等.精神分裂症患者棕榈酸帕利哌酮注射液中断治疗的相关因素分析[J].中华精神科杂志,2016,49(6):373-377
[4]谭樨.帕利哌酮联合无抽搐电痉挛治疗对精神分裂症患者记忆力的影响研究[J].四川医学,2015,36(11):1524-1526
[5]姜玮,路亚洲,史晓宁,等.精神分裂症患者临床特征和无抽搐电痉挛治疗刺激参数对疗效影响[J].中国健康心理学杂志,2014,22(10):1470-1472
[6]李东.氯氮平与MECT控制精神分裂症兴奋症状对照研究[J].中国现代药物应用,2015,9(19):132-133
[7]Dubois V,Peuskens J,Geerts P,et al.Clinical outcomes of long-acting risperidone in recent versus long-term diagnosed Belgian schizophrenic patients:Results from electronic Schizophrenia Treatment Adherence Registry(e-STAR)and trial for the initiation and maintenance of remission in schi[J].Early Intervention in Psychiatry,2014,8(1):39-49
[8]张璐璐,赵靖平.精神分裂症阴性症状的相关生物学机制与药物治疗的新发现[J].中华医学杂志,2015,95(35):2890-2892
[9]Toledo-Romero F,Molina J,López-Rodríguez E,et al.Augmentation with amisulpride for schizophrenic patients non-responsive to risperidone monotherapy[J].Pharmacopsychiatry,2015,48(2):51-57
[10]郭永芳,周小东,付华斌,等.改良电痉挛治疗对精神分裂症患者血清细胞因子及C-反应蛋白水平的影响[J].四川精神卫生,2015,28(2):119-122
[11]姜玮,路亚洲,李艳茹,等.无抽搐电痉挛治疗精神分裂症量效关系及早期预测[J].中国健康心理学杂志,2014,22(10):1473-1474
[12]肖文焕,李金,张晓斌,等.无抽搐电休克对精神分裂症患者血清脑源性神经营养因子的影响[J].国际精神病学杂志,2016,43(1):1-3
[13]董玲,安翠霞,王学义.精神分裂症认知功能损害的非药物治疗研究进展[J].中华精神科杂志,2014,47(1):56-58
[14]高海英,张淑艳,张继青,等.改良电痉挛治疗结合心理护理治疗精神分裂症的对照分析[J].河北医药,2014,36(23):3674-3675
[15]曹宏波,崔林梅,黄自州,等.齐拉西酮联合无抽搐电休克治疗精神分裂症的血清指标及电生理特征评价[J].海南医学院学报,2017,23(6):847-850
[16]强瑞香,高海江,刘炳书,等.改良电痉挛治疗与686项目结合治疗精神分裂症阳性症状[J].中国健康心理学杂志,2014,22(5):658-660